Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | XL092 |
Trade Name | |
Synonyms | XL-092|XL 092|Zanzalintinib |
Drug Descriptions |
XL092 is a receptor tyrosine kinase inhibitor that targets MET, AXL, VEGFR2, TYRO3, and MER, which potentially leads to decreased tumor cell proliferation and inhibition of tumor growth (PMID: 36399631). |
DrugClasses | MET Inhibitor 59 VEGFR Inhibitor (Pan) 36 |
CAS Registry Number | 2367004-54-2 |
NCIT ID | C161598 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
AB521 + Nivolumab + XL092 | AB521 Nivolumab XL092 | 0 | 1 |
AB521 + XL092 | AB521 XL092 | 0 | 1 |
Atezolizumab + XL092 | Atezolizumab XL092 | 0 | 1 |
Durvalumab + Tremelimumab + XL092 | Durvalumab Tremelimumab XL092 | 0 | 1 |
Ipilimumab + Nivolumab + XL092 | Ipilimumab Nivolumab XL092 | 0 | 1 |
Nivolumab + NKTR-214 + XL092 | NKTR-214 Nivolumab XL092 | 0 | 1 |
Nivolumab + XL092 | Nivolumab XL092 | 0 | 2 |
Pembrolizumab + XL092 | Pembrolizumab XL092 | 0 | 1 |
XL092 | XL092 | 0 | 4 |